Executive Director, HTA Strategy, Europe

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The companys R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Executive Director Health Technology Assessment (HTA) Strategy will lead the end-to-end execution of EU Joint Clinical Assessments (JCA) and Joint Scientific Consultations (JSC) across Revolution Medicines oncology portfolio but not limited to JCA governance timely submission delivery and post-JCA coordination with European operating countries enable efficient national HTA and payer submissions aligned with EMA addition this role will partner closely with HEOR Medical Commercial Global Market Access Clinical Development Biostatistics Regulatory and local operating country teams.

Key Responsibilities

EU JCA Leadership & Governance

• Serve as the single accountable European leader for EU JCA execution across oncology programs ensuring high-quality on-time submissions.

• Establish and lead JCA governance including cross-functional teams Member State input mechanisms and escalation pathways.

• Own EMAJCA timeline integration ensuring dossier readiness aligned to regulatory and HTA milestones.

• Lead or support Joint Scientific Consultations (JSC) to collect early HTA feedback on clinical trial design and evidence generation strategy.

JCA Scoping PICO Projection & Evidence Package Coordination

• Lead coordination of JCA scoping and PICO projection incorporating Member State input and resolving execution implications.

• Translate PICO requirements into clear evidence and dossier execution plans in partnership with HEOR Clinical Development and Biostatistics.

• Coordinate delivery and positioning of: comparative clinical effectiveness and safety evidence; subgroup sensitivity and maturity analyses; indirect treatment comparisons where required.

Cross-Functional Coordination

• Partner with Biostatistics leadership to ensure JCA-relevant analyses are prioritized and delivered within required timelines.

• Oversee cross-functional interpretation of analytical outputs to ensure consistency traceability and HTA-appropriate framing.

• Lead responses to HTA assessor questions including requests for clarification or additional analyses.

• Collaborate with global and regional cross-functional teams to contribute to the strategy and projects impacting and enabling JCA dossiers and evaluations.

JCA Dossier Development & Submission

• Own the end-to-end JCA dossier including content orchestration review cycles submission management and quality control.

• Lead interactions related to completeness checks assessor questions and factual accuracy reviews.

External Engagement & Vendor Management

• Lead or support scientific advice interactions with EU HTA bodies as relevant to JCA positioning.

• Build working relationships with assessor and co-assessor Member State HTA agencies to anticipate requirements and resolve issues proactively.

• Manage external partners and vendors supporting JCA dossier development and submission logistics.

Post-JCA Country & Global Deployment

• Translate finalized JCA outcomes into country-ready materials enabling consistent and efficient national HTA submissions and negotiations.

• Coordinate with European operating countries to ensure appropriate use of JCA conclusions and identification of local add-ons.

• Provide strategic oversight and coordination for NICE submissions ensuring alignment of evidence assumptions and positioning with JCA outcomes.

• Partner with Global Market Access and Global Evidence teams to ensure JCA outcomes are understood leveraged and reflected in global value narratives and access strategies recognizing the downstream impact of JCA conclusions beyond Europe.

Strategic Contribution

• Inform evidence generation strategy by anticipating JCA requirements early in clinical development.

• Contribute to portfolio-level access sequencing decisions based on JCA timelines and competitive positioning.

• Represent European HTA implications (EU JCA and non-EU HTAs) in relevant global governance forums.

Required Skills Experience and Education:

• Bachelors degree required; advanced degree (MSc PhD PharmD MPH MBA) strongly preferred.

• 15 years of experience in Market Access HTA or evidence leadership roles within the biopharma or biotech industry.

• Demonstrated leadership of EU multi-country HTA submissions in oncology.

• Deep familiarity with EU HTA technical assessment processes including NICE G-BA and/or HAS.

• Strong understanding of EU HTA Regulation JCA processes and EMA alignment.

• Proven ability to lead complex time-critical programs across HEOR Biostatistics Clinical Regulatory and Global Access teams.

• Executive presence with experience operating effectively in global matrixed organizations.

Preferred Skills:

• Direct experience with EUnetHTA21 pilots early scientific advice or parallel EMA-HTA consultations.

• Pre-commercial biotech experience; demonstrated ability to build processes and governance from scratch.

• Degree or certification in health economics or economic evaluation.

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect process and use any personal data that you provide to us in accordance with ourCCPA additional information please contact.

#LI-Remote #LI-LO1